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Graft versus host disease (GVHD) is an im-
mune reaction of donor lymphoid cells to anti-
gens expressed by recipients of hematopoietic 
stem cell transplantation (HSCT). In the acute 
form, occurring within 100 d after transplant, 
GVHD is a signifi  cant cause of transplant-re-
lated mortality; as a chronic disease, occurring 
sometimes indefi  nitely from 100 d after trans-
plant, it generates long-term morbidity (1).
In murine models, inactivation of recipient 
class I MHC prevents the initiation of acute 
GVHD (2) and selective class I MHC or co-
stimulatory antigen knockout implicates both 
recipient and donor APCs in the full expres-
sion of chronic GVHD (3, 4). More specifi  c 
analysis of cutaneous GVHD has revealed the 
potent function of recipient Langerhans cells 
(LC) and the attenuation of acute GVHD by 
temporal separation of donor engraftment in 
the LC and T cell compartments (5). The po-
tential persistence of recipient LC after HSCT 
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has attracted renewed attention recently. Early 
studies showed partial LC engraftment (30–75%) 
in murine radiation chimeras that were other-
wise full donor chimeras of the blood and spleen 
(6). More recently, elegant work with parabi-
otic mice and T cell–depleted transplantation 
has demonstrated conclusively that LC renew 
locally in the epidermis during the steady state 
and only summon blood-borne precursors af-
ter injury (5, 7). Together, these results suggest 
that LC are important and distinct from other 
peripheral myeloid–derived cells in the biology 
of GVHD.
Recent reports of the eff  ect of HSCT on 
human APC populations are limited to blood 
DCs. These show rapid donor repopulation in 
all transplants, in synchrony with blood my-
eloid cells (8–10). The fate of LC and other tis-
sue-derived APCs, even though they are strongly 
implicated in murine GVHD, is much less well 
known in humans. After conventional full in-
tensity transplantation (FIT), LC are depleted 
to a variable extent for weeks to months, but 
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sought to defi  ne the effect of conditioning regimes and graft versus host disease (GVHD) 
on the survival of recipient LC and reconstitution of donor cells after transplant. Confocal 
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rapidly than reduced intensity transplant (RIT) at day 0, although the nadir is similar in 
both at 14–21 d. Recovery occurs rapidly within 40 d in the absence of acute GVHD, but 
is delayed beyond 100 d when GVHD is active. LC chimerism was determined in sex-
  mismatched transplants using a two-step Giemsa/fl  uorescence in situ hybridization assay on 
isolated cells. Acquisition of donor chimerism at 40 d is more rapid after FIT (97%) than 
RIT (36.5%), irrespective of blood myeloid engraftment. At 100 d, all transplants achieve 
at least 90% LC donor chimerism and over half achieve 100%. Complete donor chimerism 
is associated with prior acute cutaneous GVHD, suggesting a role for allogeneic T cells in 
promoting LC engraftment.
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the relative contributions of conditioning therapy, cutaneous 
GVHD, and the treatment of GVHD are not clear (11–14). 
Targeted depletion of recipient APCs may be an   attractive 
means to reduce acute GVHD, but better understanding of 
the eff  ect of current conditioning regimens is required before 
this can be developed therapeutically.
Previous analysis of LC chimerism in humans is limited. 
In situ quinacrine Y-body analysis combined with OKT4 
immunohistochemistry has demonstrated donor LC in a 
single female patient (15) and a subsequent study on a small 
cohort of male patients showed persistence of recipient LC 
in some patients (16). It is known that LC can proliferate 
locally in humans from EM studies (17) and the long-term 
maintenance of donor LC after human limb transplantation 
(18). With modern reduced intensity transplant (RIT), re-
cipient LC survival after HSCT may be prolonged. This 
may delay the onset of acute GVHD after RIT (19) and 
  increase the toxicity of early donor lymphocyte infusion 
(DLI) (20, 21). More generally, the transition from recipi-
ent to donor APCs has been thought to underlie the pro-
gression of clinical GVHD from acute to chronic (22, 23). 
This is an attractive theory, but has little experimental sup-
port in humans.
In this report, we describe in detail the eff  ect of contem-
porary full and reduced intensity conditioning on human LC, 
their posttransplant reconstitution and chimerism. This pro-
vides new insights into their role in GVHD and potential as 
therapeutic targets.
RESULTS AND DISCUSSION
The impact of conditioning on LC and potential of 
therapeutic depletion
Skin biopsies were obtained pretransplant and on day 0 to as-
sess the eff  ect of RIT and FIT regimens on LC density. Intact 
epidermal sheets were examined by confocal microscopy as 
shown in Fig. 1 A. The natural arrangement of the LC net-
work in the epidermal plane is readily appreciated from a 
collapsed Z-stack image. Enumeration was precise (10.3% 
median variation between two 40× fi  elds) and sensitive 
(minimum 5 LC per mm2 ). RIT had very little eff  ect on LC 
density as illustrated by Fig. 1 A; overall, there was a 9% 
downward trend from 644 to 588 LC/mm2 (P = 0.061; Fig. 
1 B). FIT induced a 55% fall in LC from a median of 654 to 
296 LC/mm2 (P = 0.001; Fig. 1 B), a signifi  cant drop but far 
from complete ablation of the population. Patients undergo-
ing FIT were younger: median age was 34 (range: 20–54) 
compared with RIT, for which the median age was 43 (range: 
21–57; P = 0.020). Both had slightly reduced pretransplant 
counts compared with normal controls (754 LC/mm2 ), but 
this diff  erence was not signifi  cant. There was no diff  erence in 
day 0 counts with respect to alemtuzumab in conditioning 
regimens (not depicted), consistent with the observation that 
LC do not express CD52 (24, 25).
The hypothesis that recipient LC are essential in the af-
ferent arm of acute GVHD is diffi   cult to prove in humans 
without an interventional study (5). The retention of signif-
icant recipient LC on the day of transplantation is a neces-
sary condition, but other APCs such as dermal DCs may 
also play a role in sensitizing donor lymphocytes in the 
draining lymph nodes. Although LC are depleted in GVHD 
(11–14), this refl  ects the eff  erent phase of GVHD (see next 
paragraph) and cannot be used as evidence of their role in 
GVHD induction.
Most LC survive RIT conditioning and, although cyto-
kine activation may be diminished in RIT compared with 
FIT (1), the greater survival of recipient APCs may off  set this 
benefi  t. Indeed, some non T cell–depleted RIT regimens 
have a delayed yet high cumulative incidence of acute GVHD, 
approaching that of conventional transplants (19, 26).
The prospect of attenuating acute GVHD by depleting 
recipient APCs was fi  rst suggested >20 yr ago (16). Our data 
imply that there is scope to accelerate or enhance LC deple-
tion by novel conditioning therapies, such as UV light or 
monoclonal antibodies to DCs (5, 25). Others have argued 
Figure 1.  Effect of conditioning therapy on LC density. (A) Col-
lapsed Z-stack confocal image of LC in the epidermis of a 2-mm punch 
biopsy on day 0 of RIT. Bar, 200 μm. The central structure is a hair follicle. 
(B) Comparison of conditioning regimens on LC density at day 0. Median ± 
interquartile range and sample number is shown. (white bar) N, normal 
controls; (light gray bars) RIT, reduced intensity transplant; (dark gray 
bars) FIT, full intensity transplant. Pre, pretransplant (up to 14 d before the 
start of conditioning). Day 0, within 24 h of transplantation.JEM VOL. 203, January 23, 2006  29
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that complete ablation of recipient APCs might abolish graft 
versus leukemia (GVL) eff  ects (27), but a selective benefi  t 
might be gained by regional therapy of a GVHD target organ 
such as the skin.
LC recovery and the effect of GVHD
During recovery, LC density declined to a similar nadir dur-
ing 14–21 d in both types of transplant (Fig. 2 A). Although 
precise resolution of this phase is hampered by access to spec-
imens, it suggests that the earlier diff  erence between RIT and 
FIT seen at day 0 is partly kinetic (the response to RIT may 
be delayed with respect to FIT owing to the late scheduling 
of melphalan in RIT). Conditioning has a protracted eff  ect 
throughout 14–21 d, suggesting that the tissue response to 
injury and dynamics of resident APC populations is relatively 
slow or that the absence of myeloid precursors during the 
hypoplastic phase further promotes LC depletion (24).
After 28 d, there was no statistical diff  erence between 
RIT and FIT patients; so, the data were reanalyzed according 
to cutaneous GVHD at the time of biopsy (Fig. 2 B). Patients 
without GVHD recovered pretransplant median LC density 
by 40 d (537 LC/mm2 compared with 649 LC/mm2 pre-
transplant; P = 0.107), whereas those with GVHD remained 
signifi  cantly depressed at both 40 d (156 LC/mm2; P = 
0.018) and 100 d (404 LC/mm2; P = 0.006). This suggests 
that the eff  ect of conditioning, in which migration of one or 
more DC types primes the aff  erent arm of GVHD, is a dis-
tinct process to the depletion of LC that occurs later as a re-
sult of GVHD eff  ector mechanisms or corticosteroid therapy. 
In earlier studies, the high rate of early acute GVHD or “en-
graftment syndrome” at days 14–21 may have obscured this 
distinction (11–14).
Analysis of LC chimerism
Congenic markers are not universally applicable to human 
transplants; therefore, genotype analysis must be used. In situ 
methods were avoided, following the observation that exten-
sive activation of LC membrane occurs in the posttransplant 
period (Fig. 3 A). An alternate method of single cell genotyp-
ing was preferred in which cells migrating from epidermal 
sheets in vitro were subjected to two-step Giemsa/fl  uores-
cent in situ hybridization (FISH). The principal constituents 
of migratory cell preparations obtained in this way are kerati-
nocytes and CD1a-positive LC with <1% T cells or macro-
phages (Fig. 3 B). LC can be accurately identifi  ed by Giemsa 
staining alone (Fig. 3 C); this was confi  rmed in preparatory 
experiments by comparison with fl  uorescent CD1a or DR 
staining (not depicted). Approximately 20% of LC were re-
covered by migration. Although in vitro culture can exert 
selective eff  ects, there is no a priori reason to suspect that ei-
ther donor or recipient cells will be favored.
Many patients at 100 d after transplant had full donor LC 
chimerism as illustrated in Fig. 4 A. At 40 d after transplant, 
it was possible to detect mixtures of male and female cells as 
shown in Fig. 4 B. At 1 yr, a minority of patients had occa-
sional recipient cells. Fig. 4 C shows an example of 1 of 12 
recipient cells detected in 1,746 interphase nuclei examined, 
a sensitivity of <1% for recipient LC.
LC engraftment
A cohort of 32 patients (14 FIT and 18 RIT) was examined 
at 40 d, 100 d, and 1 yr after transplant (Fig. 5 A). At 40 d, the 
recovery after FIT was predominantly donor (median: 97% 
donor; range: 89–100%) compared with signifi  cant persis-
tence of recipient cells after RIT (median: 36.5% donor; 
range: 0–85%; P = 0.004). However, by 100 d, the majority 
of LC in all transplants were donor in origin with a median 
score of 100% (range: 93–100%) after FIT and 97.5% (range: 
90–100%) after RIT (P = 0.133). At 1 yr, both groups 
achieved median scores of 100% (overall range: 97–100%). 
Assuming recipient APCs are required to prime donor T cells 
for acute GVHD (2, 5) and cellular GVL responses (27), these 
events must occur within the fi  rst 100 d of fl  udarabine-me-
phalan RIT and probably within the fi  rst 40 d of conven-
tional FIT.
The delay in donor engraftment of LC in RIT is in con-
trast with rapid blood myeloid engraftment in all transplants 
by day 30 (Fig. 5 B). As expected, there was a trend for higher 
Figure 2.  Recovery of LC after transplant and suppression by acute 
GVHD. (A) Comparison of conditioning therapy: solid line, FIT; dashed line, 
RIT. (B) Comparison of clinical cutaneous GVHD at time of biopsy: solid 
line, GVHD; dashed line, no GVHD. *, P = 0.018; **, P = 0.006. The 
median ± interquartile range is given, derived from 5 to 28 samples at 
each point. x axis origin is −7 d at the pretransplant time point.30  LANGERHANS CELLS IN HEMATOPOIETIC TRANSPLANTATION | Collin et al.
LC engraftment at day 100 in patients with complete my-
eloid chimerism (P = 0.080; Fig. 5 C). However, three pa-
tients with a delayed lapse of blood myeloid chimerism at 
60–100 d (associated with declining T cell engraftment) did 
not suff  er a similar reversal of LC engraftment, although none 
achieved 100% chimerism. This suggests there is a posttrans-
plant window for LC engraftment (which may be regimen-
dependent) beyond which LC are able to maintain relative 
independence from the blood myeloid compartment.
The role of allogeneic T cells
Donor T cells promote LC engraftment in murine transplanta-
tion, under conditions of strict T cell depletion and MHC class 
II incompatibility (5). This eff  ect was not evident in the hu-
man setting of in vivo T cell depletion and geno-identical 
transplant either in the whole cohort (P = 0.759; Fig. 5 C) or 
the RIT (n = 16) or sibling RIT subgroups (n = 12; not de-
picted). However, a signifi  cant correlation between prior cu-
taneous GVHD and LC engraftment was observed (P = 0.002; 
Fig. 5 C). The induction of cutaneous GVHD, which was as-
sociated with donor T cell inoculum in the mouse, is a poten-
tial unifying mechanism for many variables that increase 
alloreactivity and enhance LC engraftment (5). Although we 
could not resolve a direct eff  ect of donor T cells, the  correlation 
of GVHD with donor chimerism confi  rms that alloreactivity 
is relevant to LC engraftment in humans. Two implications of 
this argument are that the priming phase of GVHD will be 
self-limiting and that the strategy of delayed T cell add-back 
(28) will be compromised unless adjunctive treatment, such as 
UV light, is given to ensure complete LC chimerism (5).
Figure 3.  Isolation of LC by migration in vitro. (A) Morphological 
changes in LC during the course of transplantation illustrated using anti 
CD1a-FITC and DAPI counterstain. Bar, 20 μm. (B) Flow cytometry of mi-
grant cells. LC are visible by scatter properties (left, oval region) and CD1a 
expression (right). CD3+ or CD14+ cells are <1%. The data are represen-
tative of 30 sex-matched transplants of whom 11 had active skin GVHD 
(clinical stages 1–2) at the time of biopsy. (C) Giemsa stain of epidermal 
migrants showing distinctive LC and keratinocyte morphology.
Figure 4.  Single cell genotype analysis of LC. Paired Giemsa staining 
(left insets) and X/Y FISH (right: red X probe; green Y probe; blue DAPI 
counter stain). k, recipient keratinocyte. (A) Complete donor chimerism at 
day 100 in female to male transplant. (B) 50:50 mixed chimerism at day 
40 in a female to male transplant. (C) A rare recipient cell at 1 yr, male to 
female transplant; lower autofl  uorescence in this experiment is the result 
of manual rather than automated Giemsa staining.JEM VOL. 203, January 23, 2006  31
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Clinical outcomes
Our results show that transplant regimens in clinical use pro-
mote high levels of LC engraftment by day 100. There was 
no diff  erence in event-free survival between patients who 
achieved 100% donor chimerism and those who did not, 
supporting the concept that GVHD and GVL are distinct but 
overlapping processes (Fig. S1, available at http://www.jem.
org/cgi/content/full/jem.20051787/DC1). RIT patients 
have lower LC donor chimerism at day 40, but often fi  rst 
  experience acute GVHD between 60–100 d during immu-
nosuppression withdrawal. We have argued that GVHD or 
alloreactivity is important in promoting LC engraftment and 
predict that this is increasingly important as the intensity of 
conditioning is reduced. To test this, it would be informative 
to examine LC chimerism in minimal conditioning RIT reg-
imens (29) in which acute GVHD manifestations are even 
further retarded (19).
The observation of high donor chimerism at 100 d is con-
sistent with the hypothesis that the transition of acute to 
chronic GVHD at 100 d is related to indirect antigen presen-
tation by donor APCs (22, 23). However, it now seems un-
likely that the increased toxicity of early DLI is related to 
persistence of recipient APC (20, 21), unless cells that have 
migrated have extended longevity in lymphoid tissue. An al-
ternative explanation worthy of consideration is that active 
tolerance mechanisms evolve to render DLI increasingly safe 
with time.
MATERIALS AND METHODS
Patients and biopsies. Consecutive patients who gave consent for study 
between April 2003 and June 2005 were recruited from four centers in the 
United Kingdom: Newcastle; Leeds; Christie Hospital, Manchester; and 
The Royal Free Hospital, London. 4-5-mm skin biopsies were performed 
at routine day 100 bone marrow aspiration from the posterior iliac crest. 
Additional 2- or 4-mm biopsies from the posterior iliac crest were obtained 
from patients transplanted at Newcastle at varying intervals. 184 skin bi-
opsies were obtained from 76 patients. 48 patients received RIT, the major-
ity with fl  udarabine, melphalan, and alemtuzumab (35) or fl  udarabine and 
melphalan (12). 28 patients received FIT, the majority with a total body 
irradiation regimen (16) or busulfan and cyclophosphamide (11) with or 
without alemtuzumab. All unrelated transplants, either RIT or FIT, re-
ceived a regimen containing alemtuzumab. There were 44 HLA-identical 
siblings and 32 HLA-matched unrelated donors. GVHD prophylaxis con-
sisted of pulsed methotrexate and cyclosporine or cyclosporine alone if a 
patient had received alemtuzumab. All patients were in remission or fi  rst 
chronic phase at transplantation. The median interval between prior ther-
apy and transplant was 3 mo (range: 1–10 mo); three patients treated within 
3 mo of transplant had received systemic corticosteroids. Full details of the 
patients used for LC chimerism analysis are included in Table S1 (available 
at http://www.jem.org/cgi/content/full/jem.20051787/DC1). Normal 
control skin was obtained from patients undergoing plastic surgery. All 
  procedures were performed with informed consent and ethical approval 
obtained from Newcastle and North Tyneside Local Research Ethics 
Committee, Leeds Health Authority Local Research Ethics Committee, 
South Manchester Local Research Ethics Committee, and Royal Free Hos-
pital and Medical School Ethics Committee. Clinical chimerism analysis on 
bone marrow, whole blood, myeloid (CD15+), and T cell (CD3+) fractions 
was performed according to local protocols using magnetic bead fraction-
ation and X/Y FISH or PCR of short tandem repeats. GVHD was assessed 
clinically at the time of biopsy or from case notes. Cutaneous GVHD stages 
1–2 was treated with topical betamethasone valerate 0.122%; cutaneous 
GVHD stages 3–4 or any acute GVHD grades II–IV was treated initially 
with 2 mg/kg intravenous methylprednisone and then oral prednisone 1 mg/kg 
tapered according to response.
Immunofl  uoresence  microscopy. Skin was trimmed of excess dermis 
and incubated at 37°C for 60–90 min in RPMI 1640 (Invitrogen) with 
1 mg/ml dispase (Invitrogen). Epidermal sheets were separated, fi  xed in ace-
tone for 15 min, and rehydrated in PBS (Cambrex) for 15 min. Anti-CD1a 
monoclonal NA 1/34 (DakoCytomation) was used at 1/10 dilution for 2 h 
at room temperature or overnight at 4°C. Specimens were mounted in 
Figure 5.  Donor chimerism of LC. (A) LC chimerism at 40, 100, and 
365 d after transplant for patients receiving FIT (black circles) and RIT 
(gray circles). The median percentage is depicted above the data for FIT 
and below the data for RIT. *, P = 0.004; **, P = 0.133, comparing RIT 
with FIT. (B) Blood myeloid chimerism at 30, 60, 100, and 365 d after 
transplant for patients receiving FIT (black circles) and RIT (gray circles). 
Broken lines connect samples from the same patient. The median percent-
age is depicted above the data for FIT and below the data for RIT. *, early 
relapse of chronic myeloid leukemia. (C) Distribution of LC chimerism at 
day 100 according to: (i) complete myeloid engraftment; (ii) alemtuzumab 
conditioning (T cell depletion); and (iii) prior acute cutaneous GVHD.32  LANGERHANS CELLS IN HEMATOPOIETIC TRANSPLANTATION | Collin et al.
  VectaStain containing DAPI (Vector Laboratories) and analyzed with a Leica 
TCS SP2 UV confocal microscope and LCS V 2.51 imaging software 
(Leica). Typically, 12–16 images were acquired over 20–30-μm depth at 
pixel resolution 1025 × 1025, 40× power, pinhole 1.5–1.8, and voltage 
off  set 350–500 V. In most samples, counts were the mean of two 40× fi  elds 
selected at random in the interfollicular epidermis (total area: 750 μm2 ).
Chimerism analysis. LC were allowed to migrate from 4-mm punch epi-
dermal sheets by fl  oatation on 400 μl of X-Vivo 10 medium (Biowhittaker) 
supplemented with 500 IU/ml GM-CSF (Peprotech) in a 48-well culture 
plate (Nunc) incubated at 37°C for 60 h. In sex-mismatched transplants, mi-
grant cells were harvested onto cytospin slides at 800 revolutions/min for 
4 min (Thermo Shandon) for FISH. Migratory cells from sex-matched trans-
plants were analyzed by fl  ow cytometry as described previously (25). Ap-
proximately 1,000 cells were obtained from most biopsies; examination of 
the epidermal sheet after migration revealed none remaining. Cytospin slides 
were air-dried and either stained immediately with an automated stainer 
(brighter autofl  uorescence but weaker FISH) before storage at −20°C or 
stored fi  rst and stained manually after thawing with Leishman and Giemsa 
stains 10:1 (BDH) for 5 min at room temperature (less autofl  uoresence but 
better FISH). About 20 × 20 Giemsa-stained fi  elds (100–300 LC) were lo-
cated captured and annotated using Applied Imaging Cytovision software. 
Slides fi  xed for FISH in methanol/acetic acid 3:1 for 5 min, probed with 
CEP X/Y DNA probes (Vysis) according to manufacturer’s instructions and 
mounted with VectaStain containing DAPI (Vector Laboratories). Giemsa-
stained fi  elds were reexamined and LC genotype scored. FISH images were 
recorded using Applied Imaging Smartcapture software.
Data analysis. Mann-Whitney tests were run on SPSS 12. Images were 
processed with Adobe Photoshop 7.0. Cytogenetic images were captured at 
high power and assembled as montages of several fi  elds for clarity of com-
parison with Giemsa images. Square cropping and normalizing the back-
ground were the only image adjustments made.
Online supplemental material. Table S1contains patient characteristics. 
Fig. S1 shows event-free survival according to LC engraftment. Online sup-
plemental material is available at http://www.jem.org/cgi/content/full/jem.
20051787/DC1.
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